First Parkinson's patient receives pioneering stem cell treatment in Japan

A patient in Japan has become the first to receive a pioneering stem cell treatment for Parkinson's disease using induced pluripotent stem (iPS) cells. The treatment aims to replace dopamine-producing brain cells, with plans for further clinical expansion by 2029.
Why it matters
This represents a significant medical breakthrough in regenerative medicine that could fundamentally change the treatment of degenerative neurological disorders.
A patient has undergone pioneering stem cell therapy to treat Parkinson's disease, the Japanese drugmaker behind the treatment said on Oct 30 (2026), in a world first following its conditional approval in the country.
The treatment involves transplanting millions of induced pluripotent stem (iPS) cells, which have the potential to develop into any cell in the body, into a patient's brain.
Japanese regulators approved the groundbreaking therapy in March (2026), following a successful clinical trial.
"The first transplant was performed at Kyoto University Hospital in October," the company said on Oct 30 (2026) in an earnings press release, without giving further details.
Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties with movement.
Worldwide, more than 10 million people are estimated to have the illness, according to the American non-profit Parkinson's Foundation.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in